Literature DB >> 17568238

Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study.

Gunnar Engström1, Bo Hedblad, Lars Janzon, Folke Lindgärde.   

Abstract

BACKGROUND: Complement factor C3 and C4 have been associated with atherosclerosis and cardiovascular risk factors. This study explored whether plasma levels of C3 and C4 are risk factors for the incidence of cardiovascular disease (CVD).
DESIGN: A population-based prospective study of 5850 initially healthy men, 28-61 years old at baseline.
METHODS: Plasma levels of C3 and C4 were analysed at the baseline examination. The incidence of coronary events (i.e. fatal or non-fatal myocardial infarction), ischaemic stroke and cardiovascular events (i.e. myocardial infarction, ischaemic stroke or cardiovascular death) was studied over 18 years of follow-up.
RESULTS: Adjusted for age, C3 in the fourth quartile (versus the first quartile) was associated with an increased incidence of coronary events [relative risk (RR) 1.54, 95% confidence interval (CI) 1.2-1.9], cardiovascular events (RR 1.56, 95% CI 1.3-1.9), and non-significantly with the incidence of ischaemic stroke (RR 1.31, 95% CI 0.89-1.8). However, after adjustments for smoking, body mass index (BMI), cholesterol, diabetes and systolic blood pressure, these relationships were completely attenuated and non-significant. The relationships were similar for C4 concentrations within the normal range. However, for men with C4 in the top 10% of the distribution (>0.34 g/l), a significantly increased incidence of coronary events was found, which persisted after adjustments for risk factors.
CONCLUSION: C3 and C4 show substantial correlations with cardiovascular risk factors, including blood pressure, BMI, and lipids. This relationship accounts for the increased incidence of CVD in men with high C3 levels. However, very high C4 levels may be associated with the incidence of CVD, independently of traditional cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568238     DOI: 10.1097/01.hjr.0000244582.30421.b2

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  34 in total

1.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

2.  Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Authors:  Nayareen Akhtar; Abu Taher; Rezwanur Rahman; Ashesh Kumar Chowdhury
Journal:  Heart Asia       Date:  2012-09-26

3.  Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis.

Authors:  Yaqin Wang; Yuanyi Miao; Kunjing Gong; Xuyang Cheng; Yuqing Chen; Ming-Hui Zhao
Journal:  J Cardiovasc Transl Res       Date:  2019-04-15       Impact factor: 4.132

4.  A preliminary method development study to identify potential stroke biomarkers in plasma using multiple chromatographies with nanoLC-ESIMS detection.

Authors:  Phanichand Kodali; Julio A Landero-Figueroa; Joseph Caruso; Opeolu Adeoye
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

5.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

6.  Cardiorespiratory fitness and inflammatory profile on cardiometabolic risk in adolescents from the LabMed Physical Activity Study.

Authors:  César A Agostinis-Sobrinho; Jonatan R Ruiz; Carla Moreira; Sandra Abreu; Lopes Luís; José Oliveira-Santos; Jorge Mota; Rute Santos
Journal:  Eur J Appl Physiol       Date:  2017-09-11       Impact factor: 3.078

7.  Serum complement C3 and islet β-cell function in patients with type 2 diabetes: A 4.6-year prospective follow-up study.

Authors:  Jian-Bin Su; Yun-Yu Wu; Feng Xu; Xing Wang; Hong-Li Cai; Li-Hua Zhao; Xiu-Lin Zhang; Tong Chen; Hai-Yan Huang; Xue-Qin Wang
Journal:  Endocrine       Date:  2019-11-30       Impact factor: 3.633

8.  Hypertriglyceridemia accompanied by increased serum complement component 3 and proteinuria in non-nephrotic chronic kidney disease.

Authors:  Kentaro Kohagura; Masako Kochi; Tsuyoshi Miyagi; Takanori Kinjyo; Yuichi Maehara; Kojiro Kinjyo; Kazufumi Nagahama; Atsushi Sakima; Kunitoshi Iseki; Yusuke Ohya
Journal:  Clin Exp Nephrol       Date:  2013-06-12       Impact factor: 2.801

9.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.